Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DIA08F
|
|||
| Drug Name |
SKI-G-801
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 1 | [1] | |
| Company |
Genosco
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fms-like tyrosine kinase 3 (FLT-3) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Hematopoietic cell lineage | ||||
| Pathways in cancer | ||||
| Transcriptional misregulation in cancer | ||||
| Acute myeloid leukemia | ||||
| Central carbon metabolism in cancer | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03564288) Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Genosco. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.